Laura Jopson
YOU?
Author Swipe
View article: Letter: Algorithmic <scp>NIT</scp> approaches to identify advanced liver fibrosis in patients with <scp>MASLD</scp>: Authors' reply
Letter: Algorithmic <span>NIT</span> approaches to identify advanced liver fibrosis in patients with <span>MASLD</span>: Authors' reply Open
LINKED CONTENT This article is linked to McPherson et al papers. To view these articles, visit https://doi.org/10.1111/apt.18061 and https://doi.org/10.1111/apt.18176
View article: How effective are experienced hepatologists at staging fibrosis using non‐invasive fibrosis tests in patients with metabolic dysfunction‐associated steatotic liver disease?
How effective are experienced hepatologists at staging fibrosis using non‐invasive fibrosis tests in patients with metabolic dysfunction‐associated steatotic liver disease? Open
Summary Background Sequential use of non‐invasive fibrosis tests (NITs) to identify patients with advanced hepatic fibrosis is recommended. However, it remains unclear how reliable clinicians are staging liver fibrosis using combinations o…
View article: Table of Contents
Table of Contents Open
View article: Neurosteroid Activation of GABA-A Receptors: A Potential Treatment Target for Symptoms in Primary Biliary Cholangitis?
Neurosteroid Activation of GABA-A Receptors: A Potential Treatment Target for Symptoms in Primary Biliary Cholangitis? Open
Background and Aims. A third of patients with primary biliary cholangitis (PBC) experience poorly understood cognitive symptoms, with a significant impact on quality of life (QOL), and no effective medical treatment. Allopregnanolone, a ne…
View article: Anti–Cholestatic Therapy with Obeticholic Acid Improves Short-Term Memory in Bile Duct–Ligated Mice
Anti–Cholestatic Therapy with Obeticholic Acid Improves Short-Term Memory in Bile Duct–Ligated Mice Open
View article: The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study
The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study Open
Funding by the UK Medical Research Council (Stratified Medicine Programme) and an independent research grant by Pfizer. The study funders played no role in the study design, data collection, data analyses, data interpretation or manuscript…
View article: Improved outcomes following the implementation of a decompensated cirrhosis discharge bundle
Improved outcomes following the implementation of a decompensated cirrhosis discharge bundle Open
Introduction Mortality from liver disease is increasing and management of decompensated cirrhosis (DC) is inconsistent across the UK. Patients with DC have complex medical needs when discharged from hospital and early readmissions are comm…
View article: PWE-35 Improved Outcomes Following the Implementation of a Decompensated Cirrhosis Discharge Bundle
PWE-35 Improved Outcomes Following the Implementation of a Decompensated Cirrhosis Discharge Bundle Open
Introduction Decompensated cirrhosis is a complex disorder with a high mortality rate and as a result re-admissions to hospital are common following discharge. Our aim was to evaluate the impact of implementation of a 'Decompensated Cirrho…
View article: OTH-7 Integrated care plans for alcohol-related high impact service users reduces hospital attendances and admissions
OTH-7 Integrated care plans for alcohol-related high impact service users reduces hospital attendances and admissions Open
Introduction Alcohol-related hospital admissions have doubled in the last decade to > 1.3 m per year in England. Alcohol-related high impact users are a subgroup who have multiple hospital admissions or attendances related to alcohol durin…
View article: The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis
The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis Open
Background and Aims Stratified therapy has entered clinical practice in primary biliary cholangitis (PBC), with routine use of second‐line therapy in nonresponders to first‐line therapy with ursodeoxycholic acid (UDCA). The mechanism for n…
View article: P191 Use of a decompensated cirrhosis discharge care bundle improves outcomes in patient care
P191 Use of a decompensated cirrhosis discharge care bundle improves outcomes in patient care Open
Introduction Hospital readmissions are common following discharge of patients with decompensated cirrhosis (DC). In order to try and improve the quality of patient discharge and reduce readmissions we developed a decompensated cirrhosis di…
View article: Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison
Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison Open
View article: Rituximab for the treatment of fatigue in primary biliary cholangitis (formerly primary biliary cirrhosis): a randomised controlled trial
Rituximab for the treatment of fatigue in primary biliary cholangitis (formerly primary biliary cirrhosis): a randomised controlled trial Open
Background Primary biliary cirrhosis (PBC) is an autoimmune liver disease, and 50% of patients with this disease experience fatigue. This is a debilitating symptom affecting quality of life and resulting in social isolation, which is highl…
View article: Early Molecular Stratification of High-risk Primary Biliary Cholangitis
Early Molecular Stratification of High-risk Primary Biliary Cholangitis Open
High-risk primary biliary cholangitis (PBC), defined by inadequate response at one year to Ursodeoxycholic acid (UDCA), is associated with disease progression and liver transplantation. Stratifying high-risk patients early would facilitate…
View article: The inter‐relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis
The inter‐relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis Open
Summary Background Age at presentation with primary biliary cholangitis ( PBC ) is associated with differential response to ursodeoxycholic acid ( UDCA ) therapy. Younger‐presenting patients are less likely to respond to treatment and more…
View article: Improving testing for hepatitis B before treatment with rituximab
Improving testing for hepatitis B before treatment with rituximab Open
Aims/Objectives/Background Individuals with current or previous infection with the hepatitis B virus (HBV) can experience viral reactivation when treated with immunosuppression. Rituximab, an anti-CD20 antibody used to treat many diseases,…
View article: Exercise therapy in primary biliary cirrhosis: the importance of moving while sitting on a surgical waiting list—a case study
Exercise therapy in primary biliary cirrhosis: the importance of moving while sitting on a surgical waiting list—a case study Open
Background It is being increasingly recognised that reduced cardiorespiratory fitness is associated with poorer outcomes after major surgery. Exercise limitation and reduced aerobic capacity are common in people with end-stage liver diseas…
View article: RITPBC: B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial
RITPBC: B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial Open
Introduction Primary biliary cirrhosis (PBC) is an autoimmune liver disease with approximately 50% of patients experiencing fatigue. This can be a particularly debilitating symptom, affecting quality of life and resulting in social isolati…
View article: Falk Symposium Series
Falk Symposium Series Open
View article: Subject Index Vol. 33, Suppl. 2, 2015
Subject Index Vol. 33, Suppl. 2, 2015 Open